Whilst risk management measures, including food policy, are developed for the protection of public health and 22 the environment, they may also lead to a reduction in health benefits. Policy decisions require then 23 consideration of these necessary trade-offs, which leads to an increasing need to apply formal risk-benefit 24 assessment (RBA) of foods. In this context, the European Food Safety Authority sponsored a Risk-Benefit 25 Assessment Workshop on "past, current and future developments within the risk-benefit assessment of foods 26 (RBA)" held in May 2017. The overall aims of the RBA Workshop were to discuss existing methods, challenges 27 and needs within RBA, and to draft a roadmap for future development of RBA. The specific objectives were to i) 28 identify RBA activities in Europe and globally; ii) discuss how to further develop and optimize RBA 29 methodology; iii) identify challenges and opportunities within RBA; and iv) increase collaboration 30 internationally. The two-day workshop gathered 28 participants from 16 institutions in 11 countries. It included 31 technical presentations of RBA methods and case studies, and two break-out sessions for group discussions. All 32 participants agreed that RBA has substantial potential to inform risk-management decisions in the areas of 33 food safety, nutrition and public health. Several activities to optimize further developments within RBA were 34 suggested. This paper provides a summary of workshop presentations, a discussion of challenges that limit 35 progress in this area, and suggestions of next steps for this promising approach supporting a science-based 36 decision process in the area of risk-benefit management of foods. 37 38
5 uncertainties into account. In addition, a series of initial case studies was conducted (see e.g. Boobis et al., 66 2013; Hart et al., 2013; Hoekstra et al., 2012; Hoekstra, Fransen, et al., 2013) . These projects were also 67 important to identify main challenges and limitations of the implementation of RBA at that time. After the 68 termination of these EU projects, progress in RBA has been made by individual research groups, which have 69 addressed RBA questions in ad-hoc case studies in response to questions of food safety managers (Anonymous, 70 2017a; Eneroth, Wallin, Leander, Nilsson Sommar, & Åkesson, 2017; Steffensen et al., 2018) or to make further 71 progress in RBA method development (Berjia et al., 2014; Boué, 2017) . 72 73 6
Several of the challenges identified as a result of the European RBA projects (Boobis et al., 2013) still remain, and 74 include data and knowledge gaps; methodological limitations; difficulties in aggregating/comparing risks and 75 benefits and in combining human data with data extrapolated from animal studies; lack of harmonization of 76 concepts; and complexities in communicating RBA results. Furthermore, new research questions and agendas 77 emphasize a need for assessments that include other societal impacts such as environmental, sustainability and 78 economic concerns, in addition to public health effects. Tackling these challenges and paving the way for further 79 development and implementation of RBA requires commitment and contribution of international experts in all 80 aspects of risk assessment, food safety and nutrition. International collaboration will be crucial for the 81 establishment and consolidation of RBA as a tool to evaluate scientific evidence to inform decision makers in 82 public health and food safety at national and international levels. Several research groups in different countries 83 are committed to further advance the field of RBA of foods, develop methodologies and provide evidence to 84 support risk-benefit management in food safety and nutrition at national and global level. Leveraging on these 85 research activities, EFSA sponsored a two-day workshop to gathered international RBA experts to pave the way 86 forward within the RBA area. This paper describes the structure, contents and overall conclusions of the 87 workshop. It starts by providing a brief overview of the RBA process and methodology (section 2), describes 88 examples of current developments of RBA that were presented at the workshop (section 3), as well as the most 89 important challenges within the field (section 4), and presents the opportunities and suggestions for next steps 90 within RBA discussed by the experts (section 5).1.2. Workshop objectives and structure 91
The overall aims of the RBA Workshop were to discuss methods, challenges and needs within RBA and to draft 92 a roadmap for its future development. The specific objectives were to i) identify RBA activities in Europe and 93 worldwide; ii) discuss how to further develop and optimize RBA methodology; iii) identify challenges and 94 opportunities within RBA; and iv) increase collaboration internationally. The two-day workshop gathered 28 95 participants from 16 institutions in 11 countries in Copenhagen, Denmark, May 2017. Participants and their 96 7 affiliations are presented in the appendix 1. The workshop included scientific presentations sharing past and 97 current achievements in the area of RBA; break-out discussion sessions to identify challenges and to discuss 98 opportunities for further developments in terms of data collection; methodologies and expansion of the scope 99 of RBA to include other measures of impact; and an overall discussion to plan the future of RBA. 100
Risk-benefit assessment process and methodology 101
The process of an RBA is similar to the process of a traditional risk assessment. First, the risk-benefit question is 102 defined by the risk manager, describing the purpose, scope and boundaries of the assessment including at 103 what level (component, food or diet) the assessment is performed. As part of the problem formulation, the 104 scenarios to be investigated are defined and the relevant subpopulations are identified. A reference scenario, 105 which is usually current exposure or consumption, is compared to one or more alternative scenarios. The 106 alternative scenarios serve to investigate the health impacts of a change in intake, and may be defined based 107 on for example a worst-case exposure scenario or a recommended intake. Next, the RBA process can be 108 divided into five steps, where the first four are common to the ones of traditional risk assessments but applied 109 to risks and benefits separately (Boobis et al., 2013) (Figure 1 ). Lastly, risks and benefits are integrated to 110 answer the risk-benefit question. Hence, the RBA process includes i) the identification of adverse and beneficial 111 health effects associated with the consumption of food(s) and the exposure to food components considered; ii) 112 the assessment of food consumption or exposure to food components; iii) the characterisation of the relevant 113 health effects by determining the dose-response relationships for the food components or foods, describing 114 the association between exposure and likelihood of an effect; and iv) the characterization of risks and benefits 115 by integrating the information on dose-response relationships and the outcome of the exposure assessment. 116
The conclusion of the risk-benefit characterization (i.e. step v) can be that a change in intake scenario is 117 expected to lead to an increase or decrease in the incidence of the studied health effects. This conclusion may 118 8 be based on a qualitative assessment, stating that the health impact of one scenario is beneficial as compared 119 to another without giving an estimate of the size of the health impact, but it can also be a quantitative 120 estimate, expressing the health impact in terms of a common health metric such as incidence, mortality, 121 disability adjusted life years (DALY) or quality adjusted life years (QALY) (Gold, Stevenson, & Fryback, 2002; 122 Tijhuis et al., 2012) . A quantitative assessment may be necessary if one scenario does not clearly stand out 123 more beneficial or adverse compared to another in the qualitative assessment ; 124 alternatively the aim of the RBA may be a quantitative outcome from the beginning. 125 RBA methods have evolved substantially over the years, allowing for improved evaluations of the health impact 126 of foods. These developments have been equally evident in terms of data collection and analysis, and of 127 method development and modelling (see 3.). As examples, while the first RBA studies focused on one single 128 food (e.g. fish) (e.g Skåre et al., 2015) or one single food component (e.g. folic acid 129 (Hoekstra et al., 2008) ) and investigated risks and benefits in the population as a whole, recent work has taken 130 into account the health effects of substitution of foods in overall dietary patterns, or variation in the population 131 9 frequently evaluated (Boué, Guillou, Antignac, Bizec, & Membré, 2015) . These RBA studies aimed to assess the 140 overall impact of a food consumed while considering different levels of exposure and different factors affecting 141 human health related to the fields of nutrition and/or microbiology and/or toxicology. Although many RBA 142 performed recognize the broad impact of chemical hazards, nutrients and pathogens, most of them limited the 143 analysis to only a few. For instance, the first RBA studies addressing fish consumption balanced potential 144 nutritional benefits with chemical risks without considering potential microbiological effects, whereas another 145 study on cold smoked salmon considered microbiological risks and nutritional benefits (Berjia et al., 2012) . Only 146 three out of more than 70 RBA studies included microbiological, chemical and nutritional concerns (ANSES, 147 2013; NAP, 2007; VKM, 2013), but these covered microbiology only with regard to hygiene practices 148
recommendations. 149
Until recently, several studies have made efforts to address the challenges of including all potential types of 150 risks and benefits of foods (Büchner, Hoekstra, & van Rossum, 2007 ; FAO/WHO, 2006; VKM, 2013), but none of 151 them were comprehensive by including the three fields of research, nor were they quantitative to enable 152 estimation of an overall health impact. A recent study that aimed to progress on RBA method development 153 focused on infant milk consumption during the first months of life, considering breast milk and powdered 154 infant formula . Methodological developments were investigated by taking into account a 155 limited selection of five agents relevant to the case study . The model was built to quantify 156 the risk of microbiological and chemical hazards (Cronobacter sakazakii, Cryptosporidium, dioxin like 157 polychlorinated biphenyls (dl-PCBs) and arsenic), and the benefit of nutrients (docosahexaenoic acid (DHA)) by 158 taking into account the variability in the population and data and model uncertainty . In 159 addition, to progress further on RBA methodological development, variability and uncertainty were studied 160 separately, using second-order Monte Carlo simulation. 161 10 This study's individual risk and benefit assessments components (microbiological, nutritional, and chemical) 162 involved the use of different methods, highlighting the difficulty of using a single harmonized approach. 163 Likewise, it was not possible to apply one common health metric for all health effects considered. Therefore, 164 the assessment ended with different output measures (e.g. exposure or DALYs), which hampered the 165 comparison of all health impacts in a single metric and thus restrained scenarios comparison. To overcome this 166 limitation, a scoreboard table was suggested, which also facilitated communication of RBA results while 167 providing a transparent and comprehensive overview. The RBA model developed was the first fully three-168 disciplinary and quantitative RBA performed for a single food and highlighted that the integration of different 169 methods and the assessment and communication of variability and uncertainties are still some of the 170 challenges that have to be tackled. 171
Health impact of substitution of foods 172
Changes in the intake of one food will lead to changes in the consumption of other foods, which will indirectly 173 affect the overall health impact of the food under study. If the intake of a food product is increased or 174 decreased, it either leads to a change in overall food intake, or it is compensated by a change of the rest of the 175 diet. Hence, to obtain a more integrated and realistic assessment of the overall health impact of our diet, it is 176 essential to consider the whole diet and the potential substitution of foods. Thus far, few studies have 177 addressed food substitutions in RBA. Van as more relevant, because they can account for individual preference, needs, and beliefs (Brug, Campbell, & 216 van Assema, 1999). 217
In a case-study on consumption of fish in the Danish adult population, quadratic programming models were 218 applied to generate personalized fish intake recommendations fulfilling pre-defined criteria in terms of intake 219 recommendations for EPA, DHA, and vitamin D and tolerable intake levels for methyl mercury, dioxins, and dl-220
PCBs, while simultaneously deviating as little as possible from observed individual intakes (Persson et al., 221 2018) . Such an approach has the potential to increase compliance with dietary guidelines by targeting the 222 individual consumers and minimizing the need for large and potentially unrealistic changes in consumption 223 patterns. The output is a range of intakes for different fish species that can be proposed as a personalized 224 recommendation for each individual in the population. 225
The approach of optimization of a single food recommendation can be improved by taking into account 226 individual exposures to nutrients and contaminants from other sources than the food of interest, which enable 227 refined minimum and maximum exposure criteria. The approach can also be used to optimize whole diets 
Current challenges within RBA 237
Although significant progress has been made in the development of RBA, several challenges remain (Maarten J. 238 . RBA has to face challenges of traditional risk assessment in the different disciplines, which 239 are not specific for RBA, i.e. challenges related to data availability, variability between groups of consumers and 240 individuals, strength of evidence and uncertainty in the dose response. In addition, there are challenges in 241 defining how uncertainties should be presented to policymakers and the general public, and what guidance can 242 be given to help policymakers make decisions based on uncertain evidence. Because of the parallel streams 243 assessing adverse and beneficial impacts of foods or components, RBA faces additional challenges, including 244 the integration of diverse data sources (e.g. from experimental animal studies and human epidemiological 245 studies); heterogeneity of information between risks and benefits, classification of approaches for different 246 types of risk-benefit questions (i.e. focusing on foods, food components or diets); scenario development 247 including relevant policy options; and selection of metrics to evaluate and compare risks and benefits. Lastly, 248 there are also challenges related to the current need to incorporate more than just health risks and benefits 249 (e.g.: sustainability and economic consequences) to allow policymakers to make better informed decisions, and 250 14 the consequent requirement to further develop methodologies and approaches to perform those "expanded 251 RBA". During the workshop, two categories of challenges were discussed in working groups, those related to 252 "health RBA" and those specific to "expanded RBA". 253
Challenges related to RBA of health impact of foods 254
Aligning the Risk-Benefit question and the methodological approaches 255
The formulation of a risk-benefit question precedes the RBA and is of crucial importance to ensure that the 256 RBA is focused, fit for purpose, and well-structured (Boobis et al., 2013; Hoekstra et al., 2012) . The risk-benefit 257 question will guide the choice of the RBA methodology and also the choice of risk-benefit metric. It is usually 258 the risk-benefit manager that asks the RBA question, refined as necessary in dialogue with the risk-benefit 259 assessors. Risk-benefit managers may be regulatory agencies such as national governments. However, policy 260 makers with focus in the various aspects of food are often scattered in different regulatory bodies, with distinct 261 interests, areas of action and potentially RBA questions. In addition, food companies and consumers may also 262 have the "risk-benefit manager role" and will have different interests for such assessments. As an example, 263 regulatory bodies may be primarily interested in defining safety criteria, priority setting and public health, 264 whereas consumers may have more interest in their personal dietary choices and the anticipated health 265 impacts of these choices. Hence, a broad range of risk-benefit questions and objectives are possible. For 266 example, RBA may want to consider different levels of aggregation (e.g. a food component, food product or the 267 whole diet), or the objective may be to compare specific scenarios and/or sub-populations to assess if the risk 268 exceeds the benefit or vice versa (Hans . The goal may also be to identify the most 269 advantageous intake scenario ( Development of guidance on the approaches that can be adopted for different types of risk-benefit questions 275 would facilitate the framing and the performance of RBA, and would support methodological harmonization in 276 the future. Depending on the type of question, such guidance could for example assist in the selection of food 277 components and foods as well as the health effects to be included in the RBA, and point out when quantitative 278 approaches are needed. In general, clear and continuous communication between risk-benefit assessors and 279 risk-benefit managers about the risk-benefit question and the methodological approach of choice is of crucial 280 importance to ensure fit for purpose RBA. 281
Variability between groups of consumers and individuals 282
The inherent differences between individuals may lead to the risks and benefits differing between individuals 283 and certain subpopulations (e.g. children, pregnant women, elderly). If this variability is ignored in RBA, certain 284 (groups of) vulnerable individuals suffering from higher health risks may be ignored in its conclusions, even if 285 an intake scenario, on average, is beneficial for the population. However, inclusion of variability demands 286 knowledge on potential differences in health effects between groups of consumers and individuals, and this 287 knowledge may not be available. Also, it increases the complexity of the RBA. 288
Variability is for example a concern for decisions on fortification, such as folic acid fortification of bread and 289 iodine fortification of salt. This fortification may be considered beneficial for the majority of the population, or 290 beneficial as expressed by overall population health gain, but may have negative health effects for subgroups 291 (Hoekstra et al., 2008) . Food policies such as fortification may lead to (health) winners and losers and it is an 292 ethical political question whether such a policy should be implemented. However, it is the responsibility of the 293 risk-benefit assessor to inform the policy maker of the effects on different subpopulations. Due to this different 294 16 susceptibility among the population groups, the application of folic acid fortification is still debated (Eckner, 295 Bjørn, Lunestad, & Rosnes, 2014). Taking the variability into account is crucial in RBA and can reveal population 296 groups that are at high risk or that will gain large benefit. It enables evaluation of the effect of specific 
Risk-Benefit comparison metrics 307
There are several health metrics that can be used in RBA. Fransen et al (2010) divided risk-benefit comparison 308 metrics into three categories: single outcome (e.g.: disease incidence, mortality); integrated (or summary) 309 health (e.g.: DALY and QALY); and economically oriented measures such as WTP (willingness to pay). The choice 310 of metric will depend on the type of question being asked by the risk-benefit manager and the complexity of 311 the evaluation being done. For instance, in a situation where different components affect the same endpoint in 312 an individual both positively and negatively, a net effect for the health outcome can be calculated, and 313 integrated measures might not be needed (Fransen et al., 2010; Zeilmaker et al., 2013b) . However, it is often 314 the case that risk-benefit questions are more complex and involve multiple health effects, including different 315 health effects for hazards and benefits, and therefore summary population measures such as disability 316
adjusted life year (DALY) can be helpful. For this reason, we focused our discussions during the workshop on 317 the use and challenges associated with integrated measures, more specifically DALY. 318
In recent years, the DALY has been frequently used in quantitative RBA as it is able to aggregate both mortality 319 and morbidity measures associated with several health outcomes (Murray, 1994) . It is the metric of choice for 320 the Global Burden of Disease studies (Anonymous, 2017b) , and has been shown to be a valuable instrument for 321 risk ranking of foodborne hazards (Havelaar et al., 2012 (Havelaar et al., , 2015 . It has also been applied in RBA studies to different: in the first case, it is most likely that none of the 100,000 people involved will suffer from anything; in 338 the second case, 10% of the people get ill, so around 10,000 people will be affected. If risk managers are only 339 informed about the 2 DALY and not about this difference (about 10,000 ill people versus maybe one death), 340 they may base their decisions on incomplete information. Hence, the advantage of an integrated metric, i.e. 341 that it summarizes complex issues into one figure allowing direct comparison of multiple risks and benefits, 342 may also be a disadvantage if improperly used or misinterpreted. Care should therefore always be given to 343 presenting all of the relevant underlying information (such as the basic assumptions and estimates of 344 incidence, mortality and attending uncertainty) to the decision makers. Likewise, because multiple health 345 outcomes may be considered in the total DALY estimate, the impact on the net health of one subgroup may be 346 clearly greater than for another subgroup in the population. Again, an example would be folic acid fortification 347 in which one group benefits whereas another group experiences the risks (Hoekstra et al. 2008) . The criteria for minimum weight of evidence are different in toxicology and nutrition. In general, the evidence 360 accepted to refer to a toxicological hazard as "hazard" may be much weaker than the evidence needed to refer 361 to a benefit as "benefit". In risk assessment, it is likely that a precautionary approach will be applied if there are 362 indications of a potential risk, even if the evidence is weak ( risks with a low level of evidence may be more likely to be included than nutritional benefits with the same low 367 level of evidence., This may lead to a skewed RBA. For example, the relative risk of colorectal cancer from 368 folate supplements is around 1, with an upper 95% confidence interval of around 1.2, but as high as 1.7 is some 369 studies (see (SACN, 2017)). The relative risk of a neural tube affected pregnancy is 0.29 after folic acid 370 supplements, with 95% CI of 0.12-0.71 (MRC Vitamine Study Research Group, 1991), An approach to assess an 371 upper bound risk of up to 77% increased incidence from a non-significant risk against a significant benefit of a 372 70% reduction, on average, in NTDs is still not available. This is clearly an area of RBA that needs further 373 development, such that risks and benefits can be weighted in some way for the respective levels of evidence 374
375
The characterization of the risks and benefits (i.e. the estimated health impact) is not necessarily affected by 376 this discrepancy, unless uncertainty factors that address the high uncertainty for low level evidence effects are 377 included in the dose response. However, if effects with a low level of evidence i.e. high uncertainty of 378 occurring, but potentially high health impact are ignored, the assessment could give a misleading suggestion. 379 Therefore, in communication with policymakers or risk managers, it is important to clearly address the 380 intentions of the RBA, and carefully demonstrate the assumptions in the inclusion and exclusion criteria of 381 adverse and positive health effects and their level of evidence. RBA should not be misused to play down health 382 risks associated with foods, nor should it overemphasize or ignore potential health benefits. This implies again 383 that transparency is of crucial importance for RBA, and that communication is an essential component of the 384 20 RBA process. Ultimately, it is the RBA manager that is responsible for the policy decision, and to support this 385 decision, it is the role of the RBA assessor to provide all relevant information, including an assessment of the 386 uncertainties, in as clear and transparent manner as possible, to support this. 387
Within RBA, strength of evidence is closely connected to the uncertainty assessment, which expresses the 388 belief in the obtained results. Uncertainties are propagated for example via the derived dose-response models 389 to the final DALY estimate and may, if not quantified, lead to misleading conclusions (Benford et al., 2018) . This 390 stresses the need for quantification, or at least a qualitative assessment, of uncertainties in RBA (Hart et al., 391 2013) . For RBA, the EU project Qalibra has developed a tool to include uncertainty in stochastic quantitative 392 models . The methodology of uncertainty assessment is still in development, it is not specific 393 to RBA but inherent to any science-based decision: the lack of knowledge generates imprecision in the results. 394
The impact of this imprecision has to be assessed before making decision. Sensitivity analysis is a powerful 395 technique to assess this impact (Saltelli, 2002) . In particular, it helps prioritizing additional data collection or 396 research. However, when quantification is not possible, reporting a qualitative expression of uncertainty is still 397 important as advised in the BRAFO tiered approach and illustrated in (Hoekstra, Hart, et 398 al., 2013) and (Boué, 2017) . 399
Uncertainty in the dose response 400
One of the major sources of uncertainty in RBA is the relationship between intake of a food or food component 401 and a health effect. The ideal scientific studies to establish causality between exposure to a component and a 402 health effect are randomized control trials with human participants. However, these are often not feasible for 403 ethical and/or economic reasons. Other types of studies, such as (human or animal) observational studies that 404 may reveal associations between intake of food components, contaminants, foods and diets and the likelihood 405 of a health effect, may be used alternatively. Systematic reviews and meta-analyses of all available 406 epidemiological evidence (e.g. derived by longitudinal cohort studies), which are suitable for ensuring a higher 407 21 level of evidence compared to using single studies available, are commonly used to describe the change in risk 408 of health effects associated with dietary patterns and chronic exposure to chemicals (e.g. ( The difference in methods for deriving dose response relations in RBA may be associated with different biases 428 and systematic errors, and the attending uncertainties are of a different nature. Within a research discipline, 429 these biases and errors may be relatively unimportant when risks or benefits that are derived by the same 430 22 methods are compared. But in RBA these differences may have a large impact on the output of the RBA. 431
Currently, no established methods are available to overcome these differences. Performing a sensitivity 432 analysis to highlight which sources contribute more to the overall uncertainty is recommended. 433 434
Data availability 435
The availability and quality of data is a common challenge in RBA, just as it is in traditional nutrition and risk 436 assessments. Previous reviews have identified a number of data needs and general challenges, and most of 437 these still remain (Boobis et al., 2013; EFSA, 2010; Maarten J. . There are different types of 438 data to consider: data on food consumption, levels of nutrients and contaminants in foods, microbial 439 contamination of food, background data on human disease (e.g. incidence, disability weights, pattern of 440 disease progression), and dose-responses relationships. Food consumption data may be available from national 441 dietary food surveys, which have been expanded and improved continuously (e.g. (ANSES, 2017; Pedersen et 442 al., 2010)), but it may be difficult to compare them between countries, due to differences in their design. 443
Regional databases such as the EFSA Comprehensive Food Consumption Database and harmonization guidance 444 (e.g. the EFSA's general principles for the collection of national food consumption data in the view of a pan-445
European dietary survey, known as the EU Menu) are a valuable resource to overcome these limitations and 446 ensure comparability (EFSA, 2011, 2014b). National food databases usually include information on nutrient 447 content of foods, but national monitoring data on the concentration of contaminants in foods may not be 448 available. Data from which dose-response relationships can be constructed are crucial to enable risks and 449 benefits to be estimated quantitatively. The type of data and source of information greatly differ between 450 microbiology, toxicology, nutrition, and epidemiology; and between foods, food components, and 451 contaminants. If using an integrated metric such as the DALY to compare risks and benefits, data on life 452 expectancy, disability weights and duration associated with the different health effects are needed 453 23 (Devleesschauwer et al., 2014; Hart et al., 2013) . These data are specific to the sub-population of interest but 454 rarely available at the national level. In addition, even though substantial amounts of data were published, 455 these may be available in different formats or not directly suitable for use in RBA. Increased efforts to establish 456 available, transparent and easily accessible database(s), with suitable contextual information i.e. the metadata, 457 are needed to fill these data gaps for RBA. If observational or experimental data are lacking, another option is 458 to gather information through expert elicitation (Cooke, 1991 
Challenges related to RBA including non-health related impact 464
RBA research has so far built on the principles of risk analysis for food safety, where the end-point is the human 465 health impact of food intake scenarios. However, decision makers must take into consideration factors other 466 than human health when making policy decisions (FAO/WHO, 2011; FAO, 2017). Thus, what the risk benefit 467 manager needs is a comprehensive understanding and a way to consider and balance the health impacts of 468 changes in food intake with effects on other factors such as sustainability, consumer preferences, the 469 economy, and societal values. For clarity, the question whether other disciplines should be included in the RBA 470 must be included in the risk-benefit question. Often, this question is in line with the general interests of 471 society, e.g. discuss how risk and benefits are balanced in other disciplines, including pharmaceutical drugs (H. 472 . There is consensus that, in the longer-term, RBA based only on health will not be 473 sufficient to address risk management and societal questions, and including non-health factors is inevitable and 474 necessary. This need is not unique to RBA and has been thoroughly discussed in different food-related policy 475 areas such as food safety, agriculture, the environment and nutrition (Anonymous, 2018; FAO, 2017) . Clear 476 24 priorities need to be identified at national and international levels in order to make best use of finite resources, 477 and to ensure that decisions to ensure food safety do not negatively impact on other dimensions essential for 478 development, e.g. trade, economics, food security, tourism, social well-being (FAO, 2017 ). An integrated 479 approach requires an interdisciplinary procedure as well as exchange of data from the different disciplines 480 involved. Bringing together data on safety (e.g. contamination), health aspects (e.g. nutrient composition), 481 sustainability indicators (e.g. land use) and other characteristics (such as price) concerning the same products is 482 important in order to facilitate interdisciplinary research. However, adding such factors makes the analysis 483 more complex, potentially less transparent and harder to be updated as new data becomes available. Also, it 484 increases the number of stakeholders involved, and requires a methodology in which those effects can be 485 welfare are also involved. These are all issues that carry weight individually and in society. The report is 525 concentrated on safe, healthy and sustainable diets without disregarding these other motives. Three extreme 526 scenarios were developed qualitatively, focusing on safety, health or sustainability. The scenarios were 527 analyzed and scored by exerts with a systematic group decision-support method. An attempt was made to use 528 an MCDA method to weigh different scenarios (Ocké MC, Toxopeus IB, Geurts M, Mengelers MJB, Temme 529 EHM, 2017; Saaty, 1994) . Although the method proved promising, due to the uncertainties in quantifying 530 underlying sub-criteria of indicators for sustainability, food safety and health, it was not possible to make the 531 (subjective) weighing of the different aspects transparent and the final outcome was not used. Nevertheless, 532 using expert-judgement and semi-quantification, the report concludes that opportunities to combine safety, 533 health and ecological sustainability in an integrated food policy exist. 534 535
Communication of RBA results 536
The area of risk communication has been growing and has made great progress in better understanding 537 consumer behavior, and how risk is perceived (Frewer et al., 2016) . Despite remaining challenges and 538 limitations, stakeholders are now better equipped to communicate risks to consumers. Under the risk-analysis 539 paradigm, risk assessors have also made progress in communicating with risk managers and other stakeholders 540 before, during and after a risk assessment is conducted and results are published. In most areas there is a 541 demand for decisions to be transparent, and engaging with stakeholders early-on is key. 542
Communicating RBA messages is more complex than communicating risks or benefits separately. On one hand, 543 the way risk is perceived is very different of how benefit is perceived by consumers. On the other hand, 544 27 because the overall process incorporates (at least) those two components' analyses, and their integration, the 545 data, the uncertainty around it and the assumptions are more difficult to be described, which could potentially 546 add confusion. It is important to understand the target population and establish trust by working in close 547 collaboration with stakeholders and social scientists specialized in risk communication. More research is 548 needed to understand consumer's trade-offs and values when it comes to risk and benefits of foods. Rideout 549 and Kosatsky (2017) argue that also other factors than risks and benefits associated with physical health should 550 be assessed when developing advice for specific populations (Rideout & Kosatsky, 2017) . They suggest other 551 factors to weigh in addition to health risks and benefits, such as socioeconomic and sociocultural factors, and 552
to apply e.g. health impact assessment to evaluate external impacts of a consumption advice or policy (such as 553 substitution of foods), and other qualitative tools for development of more comprehensive and effective 554 advice. 555
In addition, it is crucial that the results and methods of RBA studies are transparent and that uncertainty, when 556 possible, is taken into account and reported with the results. Likewise, it is important that the level of evidence 557 for all effects is considered, and that the limitations in available data and assumptions made are communicated 558 with the results. Especially when RBA studies are made for methodology development purposes, particular 559 care should be taken in how any preliminary results are communicated, if they do not reflect a definitive RBA. 560
Moving towards an optimal communication of RBA results to all stakeholders requires a closer collaboration 561 with social scientists. While these needs were considered and emphasized at the workshop, communication 562 tools were not the scope of the discussions. 563
Opportunities and way forward 564
As a last step, the participants of the workshop discussed the practical way forward to take RBA to the next 565 stage. Building on the challenges and opportunities identified, a number of needs and practical suggestions 566 28 were presented. In addition, activities that promote collaboration and integration of research efforts were put 567 on the agenda for a RBA Network formally launched at the event. 568
It was generally agreed that the discussions on needs, methods and challenges should now be followed by the 569 development of case studies, in which the identified challenges are addressed. Two options were identified: to 570 develop new cases using the tools and frameworks that are now available; to re-open cases that have been 571 performed previously, and apply new data and new methods to test the improvements that can be made and 572 to evaluate their robustness. Examples include probabilistic approaches that allow for the assessment of 573 variability and uncertainty and models that take substitution of foods into account. These case studies can also 574 be applied to compare different health metrics (in parallel to the DALY). The latter should preferably be 575 followed by research on the perception and communication of these different metrics to different 576 stakeholders. 577
A categorization of RBA studies will be advantageous, for example by comparing the level of aggregation of the 578 RBA (on food components, foods or diet), the risk-benefit question (which scenarios are to be compared, which 579 consumer groups are included, what food components and contaminants associated with potential health 580 effects are included), whether there is a need for a quantitative and/or stochastic approach, etc. (see section 581
Aligning Risk-Benefit question and methodological approaches, section 4.1.). Ideally, these case studies would 582 be performed by different research groups, and a platform to share and discuss their assessments should be 583 created. 584
Another generally recognized challenge within RBA is the availability of data (section 4.1). To harmonize RBA 585 internationally and to facilitate the application of RBA by national and international risk and benefit managers, 586 it is important to establish and maintain shared databases with dietary intake data, concentration data on 587 nutrients and contaminants, dose response data, data from observational studies and health data. These 588 29 databases should be transparent and easily accessible, and setting up and maintaining such a database(s) 589 would be a community effort that requires broad international support. 590
In Europe, EFSA might expand its role as curator of such databases. RBA research groups should provide input 591 to EFSA and other data providers on data needs. Furthermore, EFSA is already taking initiative to lead 592 discussions on current challenges of the integration of evidence with very diverse and not readily comparable 593 underlying evidence bases, and motivate stakeholders to address them (EFSA, 2018). Again, this should be a 594 collaborative effort with broad international support. 595
As the challenges associated to RBA are complex, expertise required are numerous and the data needs are 596 large, the workshop participants concluded that intensive international collaboration is a prerequisite for the 597 development of this novel discipline. Formalizing an RBA international network will facilitate all future activities 598 discussed and proposed in the workshop, and will help partners in consolidating and further developing current 599 activities. Ideally, such a platform should be formed within a European or global international project, to 600 ensure that harmonized approaches can be developed, and that these build on consensus in the international 601 scientific community and can serve as a basis for global decision making. Due to the unique multidisciplinary 602 character of RBA, it may be challenging to identify scientific associations and funding bodies that cover all its 603 scientific and societal aspects. Still, networking initiatives can be established, for example via research 604 applications and, at international level, with symposia organized at scientific conferences. With this in mind, 605 participants have decided to launch the International Network for Risk-Benefit Assessment of Foods. The 606 network is to be chaired by DTU Food and will be open to any group or individual with an active interest in the 607 area. Among other overall goals, this network will serve as a forum for continuation of the discussions here 608 described. 609
Overall, the workshop participants agreed that RBA is a promising and highly relevant research area that 610 deserves increased attention worldwide. Because the broad range of public-health activities associated with 611 30 foods and diets brings a high degree of complexity to policy development and a need to involve various 612 stakeholders to ensure synergy, international bodies such as the FAO have stressed that 'policy coherence' 613 across ministries is key (FAO, 2017). RBA approaches, particularly when expanded to include non-health related 614 impacts, can be a powerful tool to assist risk-managers defining policy that achieves the best societal 
